Oncology/Immuno-Oncology

Therapeutics

Developing Next Generation Therapeutics for Healthy Life

HOME / Therapeutics / Oncology/Immuno-Oncology

Pipeline

Product(Partners) Target Indication Region Discovery Preclinical IND PH1 PH2 PH3 BLA Filing
mAb for Next-Gen Immuno-Oncology Therapeutics: view more

Porustobart HBM4003

CTLA-4

Melanoma

CRC^*

HCC^*

NEN^*

Global

Global

Global

Global; view more

HBM1020

B7H7/HHLA2

Solid Tumors

Global; HBM1022

CCR8

Solid Tumors

Global; HBM9014

LIFR

Solid Tumors

Global
Immune Cell Engager for Oncology: HBM7022

CLDN18.2×CD3

Solid Tumors

Global Out-License; view more

HBM7008

B7H4×4-1BB

Solid Tumors

Global; HBM7020

BCMA×CD3

Hematologic Carcinoma

Ex-China; HBM9027

PD-L1×CD40

Solid Tumors

Global; HBM7004

B7H4×CD3

Solid Tumors

Global
XDC Platform: HBM9033

MSLN ADC

Solid Tumors

Global Out-License; ADC Program

Undisclosed

Solid Tumors

Global; RDC Program

Undisclosed

Solid Tumors

Global

Inflammatory & Immunology Diseases

Product(Partners) Target Indication Region Discovery Preclinical IND PH1 PH2 PH3 BLA Filing
FcRn-Targeted Therapies for Autoimmune Diseases: view more

Batoclimab HBM9161

FcRn

Myasthenia Gravis

Great China Rights Out-Licensed
Type 2 Pathways for Inflammatory & Immunology Diseases: HBM9378

TSLP

Asthma

COPD^*

Global

Global; BsAb Programs

TSLP×
Undisclosed

Inflammatory Diseases

Global
Pathogenic B Cell Depletion for Autoimmune Diseases: HBM7020

BCMA×CD3

Autoimmune Diseases

Ex-China; TCE Program

CD19×CD3

Autoimmune Diseases

Global; BsAb Program

Undisclosed

Autoimmune Diseases

Global; TsAb Program

Undisclosed

Autoimmune Diseases

Global

PD1 / Chemo
Breakthrough Therapy Designation

* CRC = Colorectal Cancer

* HCC = Hepatocellular Carcinoma

* NEN = Neuroendocrine Neoplasm

* COPD = Chronic Obstructive Pulmonary Disease

Publications

Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial

Tang B, Chen Y, Jiang Y, et al. J Immunother Cancer. 2024;12:e009662. doi:10.1136/ jitc-2024-009662
Batoclimab vs placebo for generalized myasthenia gravis: a randomized clinical trial

Yan C, Yue Y, Guan Y, et al. JAMA Neurol. 2024;81(4):336-345. doi:10.1001/jamaneurol.2024.0044
Generation and preclinical evaluation of a human heavy-chain-only antibody recognizing the membrane-bound tumor-associated antigen mesothelin

Janssens R, van Haperen R, van der Reijden M, et al. Front. Chem. Biol. 2024; 3:1408621. doi: 10.3389/fchbi.2024.1408621
Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and non-human primate models

Kaiser FK, Hernandez MG, Krüger N, et al. Nat Commun. 2024;15(1):2319. doi:10.1038/s41467-024-46443-0
High throughput identification of human monoclonal antibodies and heavy-chain-only antibodies to treat snakebite

Slagboom J, Lewis AH, Schouten WM, et al. Toxicon X. 2024;21:100185. doi:10.1016/j.toxcx.2024.100185
WNT/beta-catenin signalling interrupts a senescence-induction cascade in human mesenchymal stem cells that restricts their expansion

Lehmann J, Narcisi R, Franceschini N, et al. Cell Mol Life Sci. 2022;79(2):82. doi:10.1007/s00018-021-04035-x
TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China

Dong Y, Wang S, Cong L, et al. Int Ophthalmol. 2022;42(8):2459-2472. doi:10.1007/s10792-022-02245-1
An anti-CTLA-4 heavy chain-only antibody with enhanced Treg depletion shows excellent preclinical efficacy and safety profile

Gan X, Shan Q, Li H, et al. Proc Natl Acad Sci U S A. 2022;119(32):e2200879119. doi:10.1073/pnas.2200879119
A phase I study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in advanced melanoma

Presented at ESMO Immuno-Oncology Congress, 2022
Innovative B7H4 x CD3 & B7H4 x 4-1BB bispecifics for solid tumor therapies

Presented at 13th Annual Summit World Multispecifics, 2022
Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers

Yap DYH, Hai J, Lee PCH, et al. Clin Transl Sci. 2021;14(5):1769-1779. doi:10.1111/cts.13019
A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies

Wang C, van Haperen R, Gutiérrez-Álvarez J, et al. Nat Commun. 2021;12(1):1715. doi:10.1038/s41467-021-21968-w
Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes

Fu D, Zhang G, Wang Y, et al. PLoS Biol. 2021;19(5):e3001209. doi:10.1371/journal.pbio.3001209
A human monoclonal antibody blocking SARS-CoV-2 infection

Wang C, Li W, Drabek D, et al. Nat Commun. 2020;11(1):2251. doi:10.1038/s41467-020-16256-y
SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model

Haagmans BL, Noack D, Okba NMA, et al. J Infect Dis. 2021;223(12):2020-2028. doi:10.1093/infdis/jiab289
Cell Engager Summit Exclusive Speaker Interview

Presented at Cell Engager Summit, 2021
Therapeutic response and possible biomarkers in acute attacks of neuromyelitis optica spectrum disorders: a prospective observational study

Wang J, Cui C, Lu Y, et al. Front Immunol. 2021;12:720907. doi:10.3389/fimmu.2021.720907
Preclinical evaluation of HBM7022, an HBICE™ 2+1 CLDN18.2 x CD3 bispecific antibody, for gastric cancer

Presented at Antibody Engineering & Therapeutics Europe (AET Europe), 2021
Development of fully human T-cell engaging bispecific antibodies targeting B7H4

Presented at Antibody Engineering & Therapeutics Europe (AET Europe), 2021
Discovery of potent and functional human antibodies against a new B7-family member, B7H7, for cancer immunotherapy

Presented at American Association for Cancer Research Annual Meeting (AACR), 2021
Multimeric single-domain antibody complexes protect against bunyavirus infections

Wichgers Schreur PJ, van de Water S, Harmsen M, et al. Elife. 2020;9:e52716. doi:10.7554/eLife.52716
HCAb based bispecific immune cell engager (HBICE) platform enables fast and convenient generation of the next generation bispecific antibodies with high potency, promising safety profiles and excellent developability

Presented at Protein Engineering & Cell Therapy Summit Boston (PEGS Boston), 2020
HBM1022, a novel anti-CCR8 antibody, depletes tumor-infiltrating regulatory T cells via enhanced ADCC activity, mediates potent anti-tumor activity

Presented at Society for Immunotherapy of Cancer's (SITC) Annual Meeting, 2020
Novel monoclonal antibodies (mAbs) targeting human CCR8 provide potential candidates for next generation cancer immunotherapy

Presented at Protein Engineering & Cell Therapy Summit Boston (PEGS Boston), 2020
HBM1007 – A highly potent anti-CD73 mAb candidate for mono and combination IO therapy

Presented at American Association for Cancer Research Annual Meeting (AACR), 2020
BCMA x CD3 bispecific antibody – a novel HBICE™-based molecule with efficient tumor killing and minimal cytokine release

Presented at Cell Engager Summit, 2020
Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein

Widjaja I, Wang C, van Haperen R, et al. Emerg Microbes Infect. 2019;8(1):516-530. doi:10.1080/22221751.2019.1597644
A new generation of fully human anti-CTLA-4 heavy chain only antibody

Presented at American Association for Cancer Research Annual Meeting (AACR), 2019
A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity

Shi SY, Lu YW, Liu Z, et al. J Biol Chem. 2018;293(16):5909-5919. doi:10.1074/jbc.RA118.001752